(In alphabetical order)
(1) The Bill & Melinda Gates Foundation works to help all people lead healthy, productive lives, guided by the belief that every life has equal value. In support of the Sustainable Development Goals, the Foundation’s pneumonia strategy focuses on the most prevalent causes of childhood pneumonia. Our top priority is to promote full-scale delivery of currently available pneumococcal and meningococcal vaccines, and to support the development of new vaccines to improve coverage, efficacy, safety, and cost effectiveness. Because vaccines cannot prevent all cases of pneumonia and because the incidence of this disease remains high, we also work to improve access to diagnostics and treatment options which include oxygen related systems improvements in the public and private health sectors. We are developing a platform for maternal immunization to protect mothers and their newborns from pathogens that bear a disproportionate mortality burden in the neonatal period. We will continue to work though partners like Gavi, the Vaccine Alliance, to increase immunization coverage in the world’s poorest countries, and the Global Financing Facility, to help countries reach those who do not yet have access to quality services and accelerate progress on reproductive, maternal, newborn, child, and adolescent health and nutrition.
(2) The Clinton Health Access Initiative (CHAI) will work with the Governments of Ethiopia and Nigeria to increase access in both the public and private health sectors to treatment for childhood pneumonia—including oxygen for hypoxemia, and amoxicillin dispersible tablets for non-severe cases, and pulse oximetry for diagnosis. CHAI is supporting the governments to develop and implement first-ever national roadmaps for scaling up oxygen access. With support from the Bill & Melinda Gates Foundation, CHAI is supporting governments to improve the policy environment and availability of these commodities in Ethiopia (Tigray, Oromia, Amhara, and SNNPR) and Nigeria (Kano, Kaduna, and Niger states). Results and lessons from the program will benefit CHAI’s efforts in three additional countries working to reduce pneumonia deaths—including Uganda, Kenya, and India (state of Madhya Pradesh).
(3) Concern Worldwide will ensure that its country teams understand the need for more coordinated efforts to reduce child pneumonia deaths and will prioritize programs to strengthen prevention (vaccination, WASH solutions and infant/young child nutrition, including breastfeeding), diagnosis and prompt treatment as close to home as possible. Concern will intensify its efforts in the focus countries with large displaced or refugee populations to ensure that the most vulnerable children have good nutrition and safe and healthy shelter to protect them from pneumonia and other infectious diseases.
(4) The Every Woman Every Child (EWEC) Innovation Marketplace will support innovations that target the leading killers of children under five including pneumonia. Through it activities of curation and brokering, the Marketplace will identify and help to catalyze investments in child-friendly medications and devices which will improve diagnosis and treatment of pneumonia in children in low and middle-income countries.
(5) Gavi will engage governments in the focus countries with no PCV3 coverage to explore accelerated introduction of the vaccine and increase coverage of the vaccine in those focus countries with very low coverage. When introducing or expanding PCV3 coverage in the focus countries, Gavi will work with governments and other partners to ensure that other aspects of pneumonia prevention, diagnosis and treatment are integrated with vaccine promotion, training and delivery to increase impact on child lives saved and strengthen health systems.
(6) The Global Alliance for Clean Cookstoves (GACC) will raise awareness of the relationship between exposure to air pollution in the home and the risk of child pneumonia across the health, environmental pollution, climate change and women’s empowerment sectors in the focus countries. The GACC will also increase understanding, especially among governments in the focus countries with close to 100% dependence on solid fuels, that switching households to clean fuels (e.g. gas) will deliver the greatest impact on child health because it can reduce exposures by the greatest amounts. The GACC will support efforts to include household air pollution exposure in the Lives Saved Tool (LiST) so the impact of improving exposure on child survival can be routinely assessed by all stakeholders.
(7) Global Good/Intellectual Ventures will develop for the focus countries new technologies to improve child pneumonia treatment, including a reservoir mask and an oxygen storage system that can significantly increase access to oxygen in settings with unreliable treatment capacities due to unsustainable logistics or interrupted power. In addition, Global Good/Intellectual Ventures will develop better, simpler, more affordable vital sign monitoring tools to enable better management of pediatric patients. Global Good will ensure that stakeholders in the focus countries are aware of these new treatment and patient management technologies and their potential impact on child survival and of the need to invest in the critical health treatment infrastructure that can sustain oxygen systems – from generation, to delivery, to maintenance.
(8) GlaxoSmithKline (GSK) will continue to play a key role in the sustainable and accessible supply of childhood immunizations, notably through our PCV Pneumococcal Conjugate Vaccine Synflorix, as well as our respiratory, and cough & and cold medicines. Synflorix is currently used in Universal Mass Vaccination programs in more than 40 countries and, since 2010, more than 300 million doses of Synflorix have been delivered to developing countries through our partnership with Gavi under the Advanced Market Commitment (AMC). As part of this ongoing commitment, GSK will make 720 million doses of Synflorix available by the mid-2020s to help protect children in developing countries. GSK has also pledged to provide Synflorix to Civil Society Organizations (CSOs) delivering immunization programs for refugees in circumstances where governments are not able to respond. GSK and PATH are collaborating to support the implementation of the WHO recommendations for the treatment of childhood pneumonia and neonatal sepsis with amoxicillin dispersible tablets (DT). The study is focused on understanding the current pneumonia and neonatal sepsis treatment landscapes in Bangladesh and Kenya and identifying key bottlenecks that may prevent greater access to, uptake of, and appropriate use of amoxicillin DT in these countries. Depending upon the findings of the study and in collaboration with local stakeholders we intend to co-develop a strategy to address critical determinants of access and to address gaps in supply, demand and appropriate use. GSK is also committed to partnering with organizations on joint advocacy efforts to help increase awareness of the impact of pneumonia, as well as gain support from donor and local governments.
(9) Grand Challenges Canada (GCC) will evaluate for possible support through its Transition-to-Scale program pneumonia innovations that have the potential to save and improve the lives of pregnant women, newborns and children under five years of age in the focus countries. GCC is committed to stimulating the pipeline for more cost-effective innovations to improve the market for pneumonia diagnosis and treatment in low- and middle-income countries, with a focus on sustainable scale. GCC is also committed to identifying and supporting entrepreneurs and innovators with promising pneumonia technologies from the focus countries.
(10) The Barcelona Institute for Global Health (ISGlobal) will provide technical assistance in the specific areas of epidemiology, diagnostics, antimicrobial resistance and post-mortem methodologies, and their links to pneumonia. ISGlobal’s expertise in infectious diseases and respiratory health at a global level, and more particularly on the African continent, will be offered to the Every Breath Counts Coalition and ISGlobal will act as a local and global advocate to enhance pneumonia’s visibility and strengthen its recognition as one of the major threats to child survival.
(11) “la Caixa” Foundation will work to reduce pneumonia-related child mortality by increasing coverage of the PCV vaccine for pneumonia prevention; improving the diagnosis of pneumonia through the use of innovative solutions that automatically measure the respiratory rate (ARIDA) and oxygen saturation (pulse oximetry); increasing the procurement of amoxicillin dispersible tablets and access to oxygen therapy for pneumonia treatment; investing in capacity-building of frontline community health workers as they can have a significant impact in reducing child mortality by timely diagnosis and correct treatment; and raising awareness through advocacy and sensitization campaigns which would, in the medium to long term, strengthen global action and the Sustainable Development Goals agenda to end child deaths by pneumonia by 2030.
(12) Lifebox will distribute Lifebox pulse oximeters to anesthesia providers in the focus countries and train healthcare and related staff in their use, procurement and maintenance. Further, Lifebox will make the new “newborn and child-friendly” Lifebox probe available in the focus countries in partnership with Great Ormond Street Hospital for Children NHS Foundation Trust (GOSH), the Institute for Global Health at University College London (UCL), and Johns Hopkins University (JHU).
(13) McCann Global Health is committed to providing strategic communications, branding and marketing to raise awareness and deepen the impact of Every Breath Counts globally and in the focus countries. Support could include engaging influencers, executing “deep” communication efforts in the populations of mothers whose children are most at risk in the focus countries and coalescing the voices of all of the various child pneumonia stakeholders into a unified shout through a global brand platform.
(14) Malaria Consortium will develop a “Child Pneumonia Research Roadmap” to expose knowledge gaps and set research priorities, with special attention to the focus countries. Major research priorities in childhood pneumonia could include, (1) identifying the predictors of development of severe pneumonia and the children who require urgent referral or hospitalization, (2) understanding the main barriers to care seeking for children with pneumonia in different contexts, and which social and behavior change communication strategies can be effective in increasing demand for formal health services, and (3) developing diagnostic tests or diagnostic algorithms than can better detect pneumonia in children.
(15) Masimo will develop a combined pulse oximeter and respiratory rate timer specifically suited to low resource settings and increase its uptake in the focus countries, working with partners to train healthcare staff in its use, procurement and maintenance. With an initial focus on Nigeria and Ethiopia, Masimo will develop models of country engagement that can be expanded to other focus countries in future years.
(16) The Newborn Foundation will expand routine pulse oximetry testing of newborns born in hospitals in the focus countries, with an initial focus on Ethiopia and Nigeria, in partnership with Masimo. The Foundation will also explore the applications of promising new technologies that can reduce newborn deaths, especially from pneumonia, in the focus countries, including lung ultrasound – an early-stage pneumonia diagnostic innovation.
(17) Partners in Health (PiH) will use its close proximity to patient care and connections with Ministries of Health and other policy makers to advocate for increased resources for childhood pneumonia at the global level, and in the countries in which we work. We can also provide technical assistance to national governments and partners operating in the focus countries on how to strengthen all levels of pediatric pneumonia care – from the community to primary care centers to secondary- and tertiary-level hospitals. We can support application of the Mentorship and Enhanced Supervision for Health Care and Quality Improvement (MESH-QI) program, which uses clinical experts to build national capacity and train providers on best practices for the diagnosis and care of childhood pneumonia and other common illnesses.
(18) PATH will advocate at the global and national levels, including in the focus countries, for the potential of oxygen investments to contribute to the achievement of national heath goals, especially as they relate to maternal and child survival. PATH will develop a suite of evidence-based oxygen policy resources (“policy primer”) to support oxygen advocacy in low resource settings. These materials will provide country advocates with the data, messages, and tools needed to inform and engage national decision-makers and policy influencers to stimulate their support for increased access to oxygen. PATH will also work with select manufacturers of oxygen technologies to ensure that they design devices to meet the needs in low resource settings. Further, PATH supports efforts to include pulse oximetry and oxygen coverage on the Lives Saved Tool (LiST) and integrate coverage into existing global health data surveys and hospital audits. PATH will also advance the antibiotic innovation agenda by developing new heat stable, ready to use, child friendly formulations of antibiotics like “NutMox” – a new formulation of amoxicillin in a peanut butter matrix.
(19) Pfizer will build on the commitment to supply up to 740 million doses of our pneumococcal conjugate vaccine through 2025, via our partnership with Gavi the Vaccine Alliance. Pfizer also provides support for programs and disease awareness, which is intended to help improve vaccination rates. In Niger, Mali, and the DRC, Pfizer supported health care worker training intended to help people recognize the early signs of pneumonia and inform caregivers of the importance of vaccination. Plans are in place to extend this training to Angola. In addition, the Pfizer Foundation supports several programs aimed at increasing access to, and the quality of, immunizations and other health interventions. These programs are considered important to child health and survival in several countries in sub-Saharan Africa, including Ethiopia, Uganda, Malawi, Kenya, and Benin. Note the Pfizer Foundation is a charitable organization established by Pfizer Inc. It is a separate legal entity with distinct legal restrictions.
(20) Philips will work in partnership with governments, UN agencies and civil society partners to make the ChARM device available in the focus countries and will explore testing the new integrated Spot Check Monitor in one of the focus countries. In addition to improving diagnosis, Philips is committed to devices that better capture patient data and provider performance cost-effectively and which can be easily shared across large networks informing further performance improvement.
(21) Results for Development (R4D) will support activities to increase the availability and use of child pneumonia treatments in public health facilities in Ethiopia. In partnership with the Government of Ethiopia and other key stakeholders, R4D will increase awareness of amoxicillin dispersible tablets as the first-line treatment for pneumonia amongst health practitioners and policymakers at the regional and district levels; ensure that robust quantifications and financial gap analyses for amoxicillin dispersible tablets are conducted; engage with high-quality manufacturers of amoxDT to encourage registration in country; and continue to administer catalytic procurement funding while supporting the Federal Ministry of Health to mobilize domestic funding sources for amoxDT. Additionally, R4D will share learnings from its formative research in Tanzania to ascertain rates of over- and under-diagnosis of pneumonia and to identify and pilot interventions that could drive increased rational use of amoxDT. R4D’s findings could be leveraged in Coalition focus countries to improve the quality of care around childhood pneumonia.
(22) Save the Children will partner in four of the focus countries (and others) to change the trajectory of child pneumonia deaths through programming, policy, advocacy, innovations, research and campaigns. We will work to build global political attention for pneumonia mortality within the movements to end all preventable child deaths, to improve women’s children’s and adolescents’ health and nutrition, and Universal Health Coverage. We will champion innovative and equitable approaches to pneumonia prevention, diagnosis and treatment by expanding the reach and impact of the Pneumonia Innovations Network, a 350 strong global network of innovators advancing better ways to prevent, diagnose and treat child pneumonia, which will be hosted by Save the Children, and we will champion reductions in PCV vaccine pricing to reduce the costs to non-Gavi eligible countries. Save the Children’s global advocacy to end preventable child pneumonia deaths will include the education and engagement of a new generation of “influencers”, the publication of reports, and the inclusion of child pneumonia at high-level gatherings of development leaders, including at World Bank annual meetings and the UHC Forum in Japan in December, 2017.
(23) Speak Up Africa (SuA) will work through campaigns, the recruitment of high profile influencers and through quiet advocacy in any and all of the focus countries to raise the profile of pneumonia and to catalyze resource mobilization and policy change in order to reduce child pneumonia deaths. Resource mobilization will include domestic support in the preparation of investment cases for Global Financing Facility funding and policy change will focus on increasing universal access to prevention tools like immunization, breastfeeding, nutrition and diagnostic and treatment tools. A key focus will be on increasing grassroots demand for prevention, diagnostic and treatment tools through mother and caregiver focused campaigns. Speak Up Africa will identify and engage African leaders to champion action on child pneumonia in the focus countries by working with former President Kikwete, HE Moussa Faki, the leadership of the African Union, the leadership at WHO AFRO, the Organisation of African Ladies against HIV/AIDS (OAFLA), a variety of sports institutions including the Confederation of African Football and other decision-makers and influencers. Building on the child pneumonia campaigns already executed in Nigeria with the First Lady, Speak Up Africa will develop creative content for both advocacy and social behavior change targets, and assist with dissemination in other focus countries. Speak Up Africa will focus at the global level on promoting awareness of the current mismatch between the global burden of pneumonia and the small amount of global funding allocated to pneumonia.
(24) UNICEF will work in partnership with WHO and other stakeholders to accelerate child pneumonia mortality declines in the focus countries by: (1) advancing WHO pre-qualification for the medicines used to treat pneumonia, including amoxicillin dispersible tablets and antibiotic injectables for sick newborns, (2) Encouraging countries to participate to the WHO collaborative procedure for accelerated registration, and incorporating mutual recognition of registration which will help improve access where product registration could have been a barrier, (3) supporting the development of local markets and production for quality amoxicillin dispersible tablets and other medicines used to treat pneumonia, (4) improving access to new tools for early and more effective diagnosis and management of pneumonia and hypoxemia with support from “la Caixa” Foundation, and (5) improving procurement mechanisms for oxygen technologies, with support from the Bill & Melinda Gates Foundation. Further, UNICEF will provide technical support to focus countries for pneumonia prevention and treatment – including efforts to improve household air quality, breastfeeding rates and child nutrition, and PCV vaccine coverage, as well as increasing understanding of the links between these investments and child pneumonia mortality reductions. UNICEF will work closely with the US Fund for UNICEF to raise awareness and mobilize resources from US donors for the prevention, diagnosis and treatment of childhood pneumonia.
(25) The United4Oxygen Alliance, which includes companies, non-profits, and UN and government agencies, will expand its work to Nigeria, specifically to support the Government of Nigeria’s national plan to improve access to pulse oximetry screening and oxygen therapy. United4Oxygen will mobilize existing partners and engage new partners with a presence in Nigeria to, (a) increase the availability of pulse oximetry screening and oxygen therapy in health facilities, (b) train local staff in the use of new technologies, (c) establish sustainable financing solutions for the procurement, installation, and maintenance of new equipment, and (d) support the government to measure the impact of the initiative on national child survival goals. This work will be launched as a second CGI Commitment to Action and will build on best practices from the Alliance’s work in Ethiopia. United4Oxygen partners include Adara Development, Assist International, GE Foundation, Bill & Melinda Gates Foundation, Centre for International Child Health, Diamedica, Center for Public Health and Development, Gradian Health Systems, Grand Challenges Canada, Malaria Consortium, Masimo, PATH, Philips, Pneumonia Innovations Network, Save the Children, UNICEF, University of Alberta, USAID, and the World Federation of Societies of Anaesthesiologists (WFSA).
(26) The University of Melbourne’s Centre for International Child Health will support hospitals and governments in Nigeria and Ethiopia to implement effective oxygen systems through oxygen and pulse oximetry training, equipment installations, technical support, and testing of novel oxygen systems. The Centre will share results and materials from these activities for wider learning and dissemination.
(27) USAID is partnering with UNICEF to support country-led strategies to fight pneumonia within the context of their basic package of services. This will involve understanding the supply- and demand- side barriers to pneumonia prevention, diagnosis, and treatment, and will draw on best practices and innovations to overcome existing obstacles. USAID continues to focus on the prevention, diagnosis, and treatment of pneumonia as part of our overall effort to save women’s and children’s lives.